27 completed, 8 unknown, 2 recruiting, 2 terminated. 17 Phase 2, 12 Phase 3, 5 Phase 4, 3 Phase 1.
Follow BNT162b2: new trials by email Literature Review of BNT162b2 trials Research Report on BNT162b2
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Self-Amplifying mRNA COVID-19 Vaccine (LUNAR-COV19) Versus Comirnaty Vaccine in Adult Hematopoietic Cell Transplant Patients SARS-CoV-2 mRNA Vaccine ARCT-021, Tozinameran, Biospecimen Collection - Hematopoietic and Lymphatic System Neoplasm | Phase 2 | Not yet recruiting | Fred Hutchinson Cancer Center | 56 | 2026-12-01 | 2026-09-17 |
| A Study of COVID-19 Vaccine(s) in Children and Adults BNT162b2 - COVID-19 Vaccines | Phase 3 | Recruiting | BioNTech SE | 700 | 2026-08-31 | 2026-09-28 |
| A Study to Learn About How Well Yearly Updates to the COVID-19 Vaccine Work to Protect People From COVID-19 and How Much Money People Spend on Healthcare for COVID-19 BNT162b2 - COVID-19 SARS-CoV-2 Infection, COVID-19 | Active not recruiting | Pfizer | 1 | 2025-04-16 | 2025-11-19 | |
| Evaluation of COVID-19 Vaccines Given as a Booster in Healthy Adults in Indonesia (MIACoV Indonesia) Pfizer-BioNTech Standard dose, AstraZeneca Standard dose, Pfizer-BioNTech Fractional dose - COVID-19 | Phase 3 | Withdrawn | Murdoch Childrens Research Institute | 2024-04-01 | 2024-03-22 | |
| A Study to Understand is the COVID-19 Vaccine BNT162b2 is Safe in Indonesia People BNT162b2 - COVID-19 | Completed | Pfizer | 260 | 2023-03-15 | 2025-05-20 | |
| Immunogenicity and Safety of Fractional Booster Dose of COVID-19 Vaccines Available for Use in Pakistan/Brazil: A Phase 4 Dose-optimizing Trial Sinovac, AZD1222, BNT162b2 - COVID-19 | Phase 4 | Completed | Albert B. Sabin Vaccine Institute | 2354 | 2022-07-05 | 2024-01-30 |
| Evaluation of Full Versus Fractional Dose of COVID-19 Vaccine Given as a Booster for the Prevention of COVID-19 in Adults in Mongolia. Tozinameran - Standard Dose, Tozinameran - Fractional Dose - COVID-19 | Phase 3 | Completed | Murdoch Childrens Research Institute | 601 | 2022-05-27 | 2026-03-24 |
| Evaluation of Full Versus Fractional Doses of COVID-19 Vaccines Given as a Booster in Adults in Australia - Mongolia, Indonesia, Australia Coronavirus (MIACoV). Tozinameran - Standard dose, Tozinameran - fractional dose, Elasomeran - standard dose - COVID-19 | Phase 3 | Terminated | Murdoch Childrens Research Institute | 13 | 2022-05-02 | 2024-12-16 |
| Safety and Immunogenicity of BNT162b2 Coadministered With SIIV in Adults 18 Through 64 Years of Age BNT162b2, Placebo, Seasonal Inactivated Influenza Vaccine - SARS-CoV-2 Infection, COVID-19 | Phase 3 | Completed | BioNTech SE | 1134 | 2022-04-20 | 2024-06-12 |
| COVID-19 Variant Immunologic Landscape Trial (COVAIL Trial) AS03, BNT162b2, BNT162b2 (B.1.1.529) - COVID-19 | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 1270 | 2022-03-30 | 2025-10-20 |
| Myocardial Injury After BNT162b2 mRNA COVID-19 Fourth Dose Vaccination Among Israeli Health Care Workers BNT162b2 - Myocardial Injury, Vaccine Adverse Reaction | Completed | Shaare Zedek Medical Center | 336 | 2022-01-06 | 2022-05-09 | |
| Immunogenicity and Reactogenicity Following a Booster Dose of COVID-19 mRNA Vaccine (Pfizer-BioNtech) and Two Adjuvanted Sub-unit Vaccines (SP/GSK) Administered in Adults Who Received 2 Doses of Pfizer-BioNTech mRNA Vaccine as a Primary Vaccination BNT162b2, CoV2 preS dTM adjuvanted vaccine (D614), Sanofi/GSK, CoV2 preS dTM adjuvanted vaccine (B.1.351), Sanofi/GSK - COVID-19, Vaccine Reaction | Phase 3 | Unknown | Assistance Publique - Hôpitaux de Paris | 247 | 2021-12-08 | 2022-07-11 |
| The Immune Response of Heterologous Boost Third Dose of mRNA and Protein COVID-19 Vaccine BNT162b2, mRNA-1273, MVC-COV1901 - COVID-19, Breakthrough Infection | Phase 1 / Phase 2 | Unknown | Chang Gung Memorial Hospital | 340 | 2021-11-30 | 2022-07-25 |
| Randomized Trial of COVID-19 Booster Vaccinations (Cobovax Study) BNT162b2, CoronaVac - COVID-19 Vaccination | Phase 4 | Completed | The University of Hong Kong | 451 | 2021-11-18 | 2026-05-15 |
| Third Dose of mRNA Vaccination to Boost COVID-19 Immunity (mBoost Study) BNT162b2 - COVID 19 Vaccine | Phase 4 | Completed | The University of Hong Kong | 300 | 2021-10-18 | 2026-05-15 |
| Study to Evaluate Safety, Tolerability & Immunogenicity of BNT162b2 in Immunocompromised Participants ≥2 Years BNT162b2 - SARS-CoV-2 Infection, COVID19 | Phase 2 | Completed | BioNTech SE | 124 | 2021-10-15 | 2024-10-09 |
| Safety and Immunogenicity of RNA-based Vaccines Against SARS-CoV-2 Variants in Healthy Participants BNT162b2, Multivalent BNT162b2 (B.1.1.7 + B.1.617.2), Monovalent BNT162b2 (B.1.1.7) - SARS-CoV-2 Infection, COVID-19 | Phase 2 | Completed | BioNTech SE | 1380 | 2021-08-25 | 2024-11-22 |
| COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders Moderna mRNA-1273, BNT162b2, Ad26.COV2.S - Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE) | Phase 2 | Terminated | National Institute of Allergy and Infectious Diseases (NIAID) | 258 | 2021-08-13 | 2026-06-10 |
| A Trial Investigating the Safety and Effects of One or Two Additional Doses of Comirnaty or One Dose of BNT162b2s01 in BNT162-01 or BNT162-04 Trial Subjects BNT162b2s01, BNT162b2 - COVID-19, SARS-CoV-2 Infection | Phase 2 | Completed | BioNTech SE | 137 | 2021-07-26 | 2024-09-19 |
| Safety and Efficacy of COVID-19 Prime-boost Vaccine in Bahrain BBIBP-CorV, BNT162b2 - SARS-CoV 2 Infection, Covid19 | Completed | Royal College of Surgeons in Ireland - Medical University of Bahrain | 305 | 2021-07-18 | 2021-10-26 |
Showing 20 of 42. Sign in to see all of them.
COVID-19 (38) · Coronavirus Infections (8) · Severe Acute Respiratory Syndrome (4) · RNA Virus Infections (3) · Respiratory Tract Infections (3) · Virus Diseases (3) · Arthritis, Juvenile (1) · Arthritis, Rheumatoid (1) · Autoimmune Diseases (1) · Breakthrough Infections (1) · Chronic Disease (1) · Coronaviridae Infections (1) · Dermatomyositis (1) · Disease (1) · Drug-Related Side Effects and Adverse Reactions (1)
BioNTech SE (13) · Pfizer (5) · National Institute of Allergy and Infectious Diseases (NIAID) (4) · Murdoch Childrens Research Institute (3) · The University of Hong Kong (3) · Albert B. Sabin Vaccine Institute (1) · Assistance Publique - Hôpitaux de Paris (1) · Canadian Immunization Research Network (1) · Chang Gung Memorial Hospital (1) · Fred Hutchinson Cancer Center (1) · Humanity & Health Medical Group Limited (1) · Masaryk University (1) · Mebo Research, Inc. (1) · Medical University of Vienna (1) · National and Kapodistrian University of Athens (1)
United States (17) · Germany (8) · Brazil (5) · South Africa (4) · Hong Kong (3) · Japan (3) · Australia (2) · Canada (2) · China (2) · Indonesia (2) · Israel (2) · Mexico (2) · Turkey (Türkiye) (2) · United Kingdom (2) · Argentina (1)
Benjamin J Cowling, PhD (2) · Amit Bar-Or, MD, FRCP (1) · Cheng-Hsun Chiu, MD, PhD (1) · Dinesh Khanna, MBBS, MSc (1) · Eddy Fadlyana, Dr (1) · Evangelos Terpos (1) · Irene Gabashvili, PhD (1) · James R. Baker Jr., MD (1) · Joanne Langley (1) · Joshua Hill, MD (1) · Judith A. James, MD, PhD (1) · Kim Mulholland, MD (1)
PMID 37527039, PMID 39197299, PMID 32785213, PMID 33053279, PMID 33301246, PMID 33524990, PMID 34043894, PMID 34360156, PMID 34525277, PMID 34529762, PMID 34907170, PMID 35081293, PMID 35131133, PMID 35316227, PMID 35320659, PMID 35406806, PMID 35472295, PMID 35473709, PMID 35653438, PMID 35675370, PMID 35739094, PMID 35764637, PMID 35792746, PMID 35798000, PMID 35871310, PMID 35898343, PMID 36055877, PMID 36097844, PMID 36120090, PMID 36125366, PMID 36309347, PMID 36378074, PMID 36399969, PMID 36652353, PMID 36725431, PMID 37205592, PMID 37244809, PMID 37433788, PMID 37549680, PMID 37640860, PMID 37698774, PMID 37992183, PMID 38012751, PMID 38090597, PMID 38357398, PMID 39097927, PMID 39191745, PMID 39276621, PMID 39325506, PMID 40237463
5UM1AI148684-02 (1), 5UM1AI148684-03 (1)